Study on the effect of rosuvastatin treatment on the prevention of thrombosis in patients with previous thrombosis - Du Lac

Study identifier:D3560L00093

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A randomised, double-blind, placebo-controlled, event driven, phase III study of rosuvastatin 20 mg once daily in the long term prevention of recurrent venous thromboembolism in patients with deep vein thrombosis or pulmonary embolism

Medical condition

Venous thrombosis, pulmonary embolism

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin (AZD4522), Placebo

Sex

All

Actual Enrollment

3000

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2011

Estimated Primary Completion Date: 01 Mar 2013

Estimated Study Completion Date: 01 Mar 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Oral Treatment	Drug: Rosuvastatin (AZD4522) Oral dose (od) 20 mg Other Name: Crestor
Placebo Comparator: 2 Oral treatment	Drug: Placebo Oral dose (od)

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

+31 79 363 2297

marjo.tieleman@astrazeneca.com

Investigators

Principal Investigator

H. R. Büller

Academic Medical Centre